An open, non-comparative, prospective clinical study was conducted to evaluate the antihypertensive efficacy and tolerability of amlodipine, a calcium antagonist, in patients with arterial hypertension (AH) I-II stages, depending on the genotype for the polymorphic marker C3435T of the ABCB1 gene. The study included 100 patients with AH I-II stages, aged from 45 to 58 years. The initial dose of amlodipine was 5 mg, duration of treatment was 12 weeks. General clinical examination methods, office measurement and daily blood pressure monitoring, tolerance evaluation, and genotyping using the ABCB1 polymorphic marker C3435T by the PCR-RFLP method (polymerase chain reaction and restriction fragment length polymorphism) were used. The statistical analysis of results was carried out using the Mann-Whitney U test for quantitative variables, Kruskal-Wallis one-way analysis of variance (ANOVA) for three independent groups of quantitative data. Excellent antihypertensive efficacy with the CC genotype was found in 11.8% patients, with CT – 33.9%, with TT – 43.3%; good – 35.3%, 32.1%, and 33.3% respectively, satisfactory – 52.9%, 34,0% and 23.4% respectively. Six patients with the CT genotype and nine patients with the CC genotype required the increase in the dose to 10 mg. The number of patients with Adverse drug reactions (ADR) were found in 35.3% of patients with the CC genotype, 6.7% with the TT genotype and 11.3% with the CT genotype. The Kruskal-Wallis test revealed significant differences between CC and TT genotypes in the degree of decrease in SBP (p=0.02), antihypertensive efficacy parameter (p=0.02), an increase in dose requirements (p = 0.04) and the incidence of ADR(p=0.05). In AH patients (I-II stage) with the TT genotype of the C3435T gene polymorphism one can expect higher rates of antihypertensive efficacy of amlodipine in combination with a good safety profile and the lowest ADR percentage, while patients with the CC genotype more likely to develop ADR and lower antihypertensive responsiveness.
Sychev D.A. и др., Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension //Biomeditsinskaya khimiya.- 2017. -Т.63. -№ 5. С. 432-439.
Sychev D.A. и др., "Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension." Biomeditsinskaya khimiya 63.5 (2017): 432-439.
Sychev D.A., Shih N.V., Kalle E.G., Ryzhikova K.A., Morozova T.E. (2017). Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension. Biomeditsinskaya khimiya, 63(5), 432-439.
2013 Guidelines for the Management ofArterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) J Hypertens., 31(7), 1281-1357. Scholar google search
Diagnostika i lechenie arterial'noj gipertonii. Klinicheskie rekomendatsii. (2015) Kardiologicheskij Vestnik, 10(1), 3-31. Scholar google search
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016) Euro. Heart J., 37, 2315-2381. Scholar google search
“Ob utverzhdenii standarta pervichnoj mediko-sanitarnoj pomoshchi pri pervichnoj arterial'noj gipertenzii (gipertonicheskoj bolezni)”. Prikaz Ministerstva zdravookhraneniya Rossijskoj Federatsii ot 9 noyabrya 2012 g. №708n. https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/stranitsa-983/1-standartypervichnoy-mediko-sanitarnoy-pomoschi/klass-ix-boleznisistemy-krovoobrascheniya-i00-i99 Scholar google search
The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) (2000) JAMA, 283, 1967-1975. Scholar google search